Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. (A) Kaplan-Meier plot comparing V gene mutation status with survival among the cases within the Rai intermediate risk category (unmutated: 16 cases; mutated: 9). Median survival of the mutated group: 9 years; median survival of the unmutated group: 17 years (P = .0007; log-rank test). (B) Kaplan-Meier plot comparing numbers of CD38+ B-CLL cells with survival among the cases within the Rai intermediate risk category (≥30%: 11 cases; <30%: 9). Median survival of the 30% CD38+ group: 10 years; median survival of the <30% CD38+ group: not reached (P = .0030; log-rank test). None of the patients in the <30% CD38+ group died during the follow-up period. Rajendra N. Damle et al. Blood 1999;94:1840-1847 ©1999 by American Society of Hematology